RU95118436A - HORMONAL SUBSTITUTION THERAPY - Google Patents

HORMONAL SUBSTITUTION THERAPY

Info

Publication number
RU95118436A
RU95118436A RU95118436/14A RU95118436A RU95118436A RU 95118436 A RU95118436 A RU 95118436A RU 95118436/14 A RU95118436/14 A RU 95118436/14A RU 95118436 A RU95118436 A RU 95118436A RU 95118436 A RU95118436 A RU 95118436A
Authority
RU
Russia
Prior art keywords
antiprogestin
amount
estrogen
administered
kit
Prior art date
Application number
RU95118436/14A
Other languages
Russian (ru)
Other versions
RU2139056C1 (en
Inventor
Д.Ходжен Гари
Original Assignee
Дзе Медикал Колледж оф Хэмптон Роудс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/023,692 external-priority patent/US5468736A/en
Application filed by Дзе Медикал Колледж оф Хэмптон Роудс filed Critical Дзе Медикал Колледж оф Хэмптон Роудс
Publication of RU95118436A publication Critical patent/RU95118436A/en
Application granted granted Critical
Publication of RU2139056C1 publication Critical patent/RU2139056C1/en

Links

Claims (21)

1. Способ гормональной заместительной терапии, включающий введение женщине, нуждающейся в такой терапии, эстрогена в эффективном с точки зрения гормональной заместительной терапии количестве и антипрогестина в количестве, эффективном для подавления вызываемого эстрогеном разрастания эндометрия и осуществления состояния существенной аменореи, в отсутствие применения прогестина.1. A method of hormone replacement therapy, comprising administering to a woman in need of such therapy estrogen in an amount effective from the point of view of hormone replacement therapy and an antiprogestin in an amount effective to suppress estrogen-induced proliferation of the endometrium and to achieve a significant amenorrhea state in the absence of progestin. 2. Способ по п. 1, в котором антипрогестин вводят ежедневно. 2. The method of claim 1, wherein the antiprogestin is administered daily. 3. Способ по п. 2, в котором введение перорально. 3. The method of claim 2, wherein the administration is oral. 4. Способ по п. 1, в котором эстроген и антипрогестин вводят ежедневно. 4. The method of claim 1, wherein estrogen and antiprogestin are administered daily. 5. Способ по п. 1, в котором введение перорально. 5. The method of claim 1, wherein the administration is oral. 6. Способ по п. 1, в котором с каждым приемом вводится приблизительно от 0,5 до 10 мг антипрогестина ежедневно. 6. The method according to p. 1, in which with each dose is administered from about 0.5 to 10 mg of antiprogestin daily. 7. Способ по п. 6, в котором вводимое количество составляет приблизительно от 1 до 5 мг. 7. The method of claim 6, wherein the amount administered is from about 1 to 5 mg. 8. Способ по п. 1, в котором введение осуществляется в режиме депо. 8. The method according to p. 1, in which the introduction is carried out in depot mode. 9. Способ по п. 1, в котором антипрогестин является антагонистом прогестинового рецептора. 9. The method of claim 1, wherein the antiprogestin is an antagonist of the progestin receptor. 10. Способ по п. 9, в котором антипрогестин представляет собой RU 486. 10. The method of claim 9, wherein the antiprogestin is RU 486. 11. Способ по п. 1, в котором количество введенного антипрогестина сохраняет костно-консервирующее действие введенного эстрогена. 11. The method according to p. 1, in which the amount of antiprogestin administered preserves the bone-preserving effect of the administered estrogen. 12. Способ по п. 1, в котором введение продолжается в течение минимального интервала в 20 дней. 12. The method of claim 1, wherein administration is continued for a minimum interval of 20 days. 13. Способ гормональной заместительной терапии, в котором эстроген вводят в отсутствие приема прогестина женщине, нуждающейся в такой терпии, отличающийся дополнительным введением указанной женщине антипрогестина в количестве, которое подавляет вызываемое эстрогеном разрастания эндометрия и которое позволяет осуществить состояние существенной аменореи. 13. A method of hormone replacement therapy, in which estrogen is administered in the absence of progestin to a woman in need of such patience, characterized by the additional administration of the antiprogestin indicated to the woman in an amount that suppresses the estrogen-induced endometrial proliferation and which allows for a significant amenorrhea condition. 14. Набор, содержащий определенное количество таблеток, часть которых содержит эффективное с точки зрения гормональной заместительной терапии количество эстрогена и часть которых содержит количество антипрогестина, которое подавляет вызываемое эстрогеном разрастание эндометрия и которое позволяет осуществить состояние существенной аменореи. 14. A kit containing a certain number of tablets, some of which contain an effective amount of estrogen from the point of view of hormone replacement therapy, and some of which contain an amount of antiprogestin, which inhibits estrogen-induced overgrowth of the endometrium and which allows the state of significant amenorrhea to be realized. 15. Набор по п. 14, в котором каждая таблетка содержит как эстроген, так и антипрогестин. 15. The kit of claim 14, wherein each tablet contains both estrogen and antiprogestin. 16. Набор по п. 15, в котором количество антипрогестина составляет приблизительно от 0,5 до 10 мг. 16. The kit of claim 15, wherein the amount of antiprogestin is from about 0.5 to 10 mg. 17. Набор по п. 16, в котором количество антипрогестина составляет приблизительно от 1 до 5 мг. 17. The kit according to claim 16, in which the amount of antiprogestin is approximately 1 to 5 mg. 18. Набор по п. 17, в котором антипрогестин представляет собой RU 486. 18. The kit according to claim 17, in which the antiprogestin is a RU 486. 19. Набор по п. 14, в котором количество антипрогестина составляет приблизительно от 0,5 до 10 мг. 19. The kit according to claim 14, in which the amount of antiprogestin is approximately from 0.5 to 10 mg. 20. Набор по п. 14, в котором количество антипрогестина составляет приблизительно от 1 до 5 мг. 20. The kit according to claim 14, in which the amount of antiprogestin is approximately 1 to 5 mg. 21. Набор по п. 14, в котором антипрогестин является антагонистом прогестинового рецептора. 21. The kit of claim 14, wherein the antiprogestin is a progestin receptor antagonist.
RU95118436/14A 1993-02-25 1994-02-18 Hormonal substitutional therapy RU2139056C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/023692 1993-02-25
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy
PCT/US1994/001815 WO1994018983A1 (en) 1993-02-25 1994-02-18 Hormone replacement therapy

Publications (2)

Publication Number Publication Date
RU95118436A true RU95118436A (en) 1998-01-10
RU2139056C1 RU2139056C1 (en) 1999-10-10

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95118436/14A RU2139056C1 (en) 1993-02-25 1994-02-18 Hormonal substitutional therapy

Country Status (25)

Country Link
US (1) US5468736A (en)
EP (1) EP0686037B1 (en)
JP (1) JP3441459B2 (en)
KR (1) KR100248857B1 (en)
AT (1) ATE202281T1 (en)
AU (1) AU680239B2 (en)
BG (1) BG62383B1 (en)
BR (1) BR9406667A (en)
CA (1) CA2157003C (en)
CZ (1) CZ290562B6 (en)
DE (1) DE69427529T2 (en)
DK (1) DK0686037T3 (en)
ES (1) ES2159552T3 (en)
FI (1) FI953926A0 (en)
GR (1) GR3036649T3 (en)
HU (1) HU221169B1 (en)
NO (1) NO309456B1 (en)
NZ (1) NZ262657A (en)
PL (1) PL176796B1 (en)
PT (1) PT686037E (en)
RO (1) RO115115B1 (en)
RU (1) RU2139056C1 (en)
SK (1) SK282921B6 (en)
UA (1) UA43842C2 (en)
WO (1) WO1994018983A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
MX9301121A (en) 1992-03-02 1993-09-01 Schering Ag METHOD AND EQUIPMENT FOR ORAL CONTRACEPTION AND REGULATION OF MENSTRUATION WITH ESTROGEN / PROGESTIN / ANIPROGESTIN.
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
DE19610635A1 (en) * 1996-03-11 1997-09-18 Schering Ag Sequential estrogen / progesterone antagonist combination for hormone replacement therapy
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
CO5200773A1 (en) * 1999-08-31 2002-09-27 Jenapharm Gmbh And Co Kg MESOPROGESTINES (RECEIVER MODULATORS FOR PROGESTERON) AS A COMPONENT OF COMPOSITIONS USED FOR HORMONAL REPLACEMENT THERAPY (HRT)
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE60217324T2 (en) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. PHARMACEUTICAL COMPOSITION FOR HORMONE SUB-THERAPY
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ES2337129T3 (en) * 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. MEDICINAL ADMINISTRATION SYSTEM UNDERSTANDING A TETRAHYDROXYLED STROGEN FOR USE IN HORMONAL ANTI-CONCEPTION.
DK1390042T3 (en) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administering a drug comprising tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60216630T2 (en) * 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. USE OF ESTROGEN IN COMBINATION WITH PROGESTOGEN FOR HORMONE SUBSTITUTIONAL THERAPY
DE10206089A1 (en) 2002-02-13 2002-08-14 Zimmer Ag bursting
CA2489271C (en) * 2002-06-11 2011-12-06 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
AU2003274941A1 (en) * 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
ES2299730T3 (en) * 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. PHARMACEUTICAL COMPOSITION THAT INCLUDES STETROL DERIVATIVES FOR USE IN CANCER THERAPY.
SI1556058T1 (en) * 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
PT1624878E (en) * 2003-05-22 2007-01-31 Pantarhei Bioscience Bv Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
EP3693376A1 (en) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Compositions for suppressing endometrial proliferation
DE602008001783D1 (en) * 2007-01-08 2010-08-26 Pantarhei Bioscience Bv METHOD FOR TREATING OR PREVENTING BARRENESS OF FEMALE ANIMALS AND PHARMACEUTICAL KIT FOR THE USE OF THIS METHOD
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (en) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
SI3310333T1 (en) 2015-06-18 2020-08-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (en) * 1992-03-02 1993-09-01 Schering Ag METHOD AND EQUIPMENT FOR ORAL CONTRACEPTION AND REGULATION OF MENSTRUATION WITH ESTROGEN / PROGESTIN / ANIPROGESTIN.

Similar Documents

Publication Publication Date Title
RU95118436A (en) HORMONAL SUBSTITUTION THERAPY
KR960700727A (en) HORMONE REPLACEMENT THERAPY
ES2206487T3 (en) AGENT AND PROCEDURE FOR HORMONAL CONTRACEPTION AND / OR FOR THE TREATMENT OF ACNE.
RU2091069C1 (en) Agent for hormonal contraception that inhibits ovulation
RU2245713C2 (en) Interrupted hormone-substitution therapy with low estrogen dosages
AU705618B2 (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
RU96115196A (en) COMPOSITION FOR CONTRACEPTION
EP1689411B1 (en) Graduated estrogen contraceptive
US6797282B2 (en) Combination progestin oral contraceptive regimen
IL94416A (en) Pharmaceutical compositions containing dihydrospirorenone
NZ234051A (en) Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity
RU99101114A (en) PROGESTOGEN-ANTIPROGESTOGEN RECEPTION DIAGRAMS
UA41401C2 (en) Pharmaceutical combined contraceptive agent
CA2468748A1 (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HUP9900612A2 (en) Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies
RU2000115313A (en) GESTAGEN-ANTI-GESTAGEN RECEPTION DIAGRAMS
EP1007052B1 (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
NO169322B (en) FERTILIZATION PREVENTING SYNERGISTIC EFFECT
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
CA2444980A1 (en) Single dose aromatase inhibitor for treating infertility
RU95118417A (en) METHOD OF PREVENTION OR DELAY IN FERTILIZATION
Adashi The morning after: novel hormonal approaches to postcoital interception
AU2003206424B2 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
AU2005201151B2 (en) Low dose estrogen interrupted hormone replacement therapy
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)